

**I. AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

Claims 1-14. (Cancelled)

Claim 15. (Currently amended) A method of treating a mammal having metabolic abnormalities resulting from insulin resistance comprising administering an effective amount of ~~a at least one~~ polymethoxyflavone ~~compound~~ composition comprising sinensetin, nobiltin, tangeretin, heptamethoxyflavone and tetramethylscutellarein to reduce serum insulin levels by at least about 26%.

Claims 16-19 (Cancelled)

Claim 20. (Currently amended) The method of claim 15 wherein said ~~at least one~~ polymethoxyflavone composition is administered by a means chosen from oral, transdermal, rectal, intravenous, intramuscular, intraperitoneal subcutaneous, topical, or by inhalation.

Claim 21. (Currently amended) The method of claim 15 wherein said ~~at least one~~ polymethoxyflavone composition is administered orally.

Claim 22. (Currently amended) The method of claim 15 wherein said ~~at least one~~ polymethoxyflavone composition is administered to said mammal in an amount of up to 5000 mg/day.

Claim 23. (Currently amended) The method of claim 22 wherein said ~~at least one~~ polymethoxyflavone composition is administered to said mammal in an amount of up to 70 mg/kg/day, based on the weight of said mammal.

Claim 24. (Cancelled)

Appl. No. 10/697,563  
Amdt. dated December 8, 2005  
Reply to Office Action of August 8, 2005

Claim 25. (New) The method of claim 15, wherein said polymethoxyflavone composition comprises about 9.3% sinensetin, about 35%, about 11.1% tangeretin, about 33.5% heptamethoxyflavone and about 11.1% tetramethylscutellarein.